Nadine Defranoux PhD

Dr. Nadine Defranoux is currently a Program manager at the Parker Institute for Cancer Immunotherapy (PICI), a non-profit institute focused on accelerating breakthrough research in immuno-oncology. Dr. Defranoux joined PICI in 2016 and leads the Tumor neoantigEn SeLection Alliance (TESLA), a joint initiative with the Cancer Research Institute (CRI) aimed at optimizing approaches to identify actionable immunogenic neoantigens. She has a significant expertise and experience in leading collaborative research programs with pharma and academic groups in areas of inflammation, infectious diseases and cancer.